Gold Coast, Australia (January 3, 2020): The results of a randomized, placebo-controlled, double-blind clinical  trial of perispinal etanercept were published today, confirming the efficacy and remarkable results of perispinal etanercept in a cohort of stroke survivors with relentless, intractable daily pain after stroke. The individuals were treated an average of about 4 years after stroke and each reported constant daily pain after their stroke that had failed to adequately respond to all previous forms of treatment. They received two doses of perispinal etanercept, each two weeks apart, with the control group receiving two doses of saline administered perispinally. The control group had no change in their daily pain, but the etanercept group had a significant reduction in pain, measured at 30 days, with 30% of the etanercept patients showing near complete pain abatement after the first etanercept treatment. The study concludes: “Perispinal etanercept can provide significant and ongoing benefits for the chronic post-stroke management of pain and greater shoulder flexion by the paretic arm. Effects are rapid and highly significant, supporting direct action on brain function.”

The clinical trial results published on January 3, 2020 in the journal  Expert Opinion on Investigational Drugs. Learn More.

href=”https://www.strokebreakthrough.com/about/terms-of-use/”>Terms of Use</a>

Improvement in neurological signs and symptoms of thalamic syndrome (Dejerine-Roussy Syndrome) due to a stroke 20 years previously (in 1998) after treatment at the Institute of Neurological Recovery in Boca Raton in September 2018, by Edward Tobinick, M.D. Text, images and video © 2018, INR PLLC, all rights reserved.

Request a consultation today
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

Rapid Improvement in Walking, Balance, Tone & Cognition 3 Years After Stroke

From Kentucky to the INR in Boca Raton, Florida. Published July 16, 2018.

Request a consultation today
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

Invited editorial by Edward Tobinick, MD, entitled, “Perispinal etanercept advances as a neurotherapeutic” published in Expert Review of Neurotherapeutics, on April 25, 2018.

Walking without a stick (cane) after treatment at the INR! Eddie and his family from Scotland, visiting the INR Boca Raton, on April 23, 2018.

Request a consultation today
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

She has written an update on her progress! See it here!

Request a consultation today
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

Request a consultation today
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

Patient and father, from Iceland, discusses improvements 2 years after stroke. The stroke happened at age 17. Improvements discussed include: spasticity, left neglect, walking, speech, fatigue, and improved ability to swallow.

Request a consultation today
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use

Treatment at the Institute of Neurological Recovery in Boca Raton, Florida, March 6, 2018, twenty two months after stroke. Immediate improvements in aphasia, apraxia of speech, walking, etc.

Request a consultation today | Terms of Use & Disclaimer

Click here to see Part 1.

Request a consultation today
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use